Thermo Fisher Scientific (TMO) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $257.42B, a trailing price-to-earnings ratio of 28.1 and a free-cash-flow yield of 2.4%. Over the most recent reported fiscal year, revenue grew 3.9% and free cash flow per share fell 12.3%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 5.9/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Rising · +17.0% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-2.4%
How far the last close sits under the highest price of the past five years.
Market cap
$257.42B
Trailing P/E
28.1
Price / book
4.9
Price / sales
5.4
FCF yield
2.4%
Dividend yield
0.3%
Gross margin
40.8%
Operating margin
18.3%
Net margin
15.0%
Revenue growth (YoY)
+3.9%
Revenue growth (3-yr annual)
-0.3%
EPS growth (YoY)
+4.6%
FCF/share growth (YoY)
-12.3%
Beta
0.9
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics Research
TMO earnings
Next report: Jan 28, 2027 (Q4 2026, EPS estimate $7.13).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 21, 2026
$6.68
$6.40
+4.4%
$12.14B
Q2 2026
Jul 23, 2026
$6.03
$5.71
+5.6%
$11.99B
Q1 2026
Apr 23, 2026
$5.44
$5.24
+3.8%
$11.01B
Q4 2025
Jan 29, 2026
$6.57
$6.45
+1.9%
$12.21B
TMO analyst price target
Median target $750.00 from 25 analysts, ranging $590.00 – $830.00.
Nama's AI scorecard currently rates Thermo Fisher Scientific Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TMO's P/E ratio?
Thermo Fisher Scientific trades at a trailing price-to-earnings ratio of 28.1.
When does TMO report earnings?
Thermo Fisher Scientific's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $7.13.
What is the TMO price target?
The median analyst price target from 25 analysts is $750.00, with a range of $590.00 – $830.00.
Is TMO Shariah compliant?
Nama's AAOIFI-style screen reads Thermo Fisher Scientific as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does TMO pay a dividend?
Yes — Thermo Fisher Scientific's dividend yield is 0.3%.